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Summary In a series of 22 patients, high dose BCNU (800-1,000 mgm-2) with autologous bone marrow
transplantation was given as the first post-surgical treatment for grade IV astrocytoma and followed by full
dose radiotherapy. When compared to historical experience and matched to control patients in national
studies, there appeared to be a small prolongation of survival but no increase in the proportion of long
survivors. Acute myelosuppression was mild but toxicity to lung and liver was substantial and limited further
dose escalation. Late bone marrow failure was seen in 4 patients. Pharmacokinetic studies were performed
and suggested that the late marrow failure was due to persistence of BCNU at the time of marrow return.
Despite the suggestion of a prolongation of survival this approach is not routinely recommended and a
randomised trial is probably not justified.
The management of high grade glioma is unsatisfactory
(Bloom, 1982). Radiotherapy following surgery will prolong
survival by several months but long term survivors from
grade IV astrocytoma (glioblastoma multiforme) are rare.
Conventional chemotherapy has little to offer. These
tumours share the relatively poor cellular chemosensitivity of
most solid human cancers. In addition penetration of drugs
into high grade gliomas is poor. They often have poor
vascularisation and probably also a partially intact blood-
brain barrier in parts of the tumour (Workman, 1986).
BCNU (carmustine, 1,3-bis(2-chloroethyl)-l-nitrosourea)
has been tested in conventional doses following surgery and
radiotherapy for the treatment of high grade glioma. It gives
a small, statistically significant, prolongation of survival but
overall results are still poor with a median survival of only
12 months (Walker et al., 1980; Green et al., 1983). The dose
of BCNU that can be given is limited by myelosuppression
which is characteristically later in onset than that seen with
most cytotoxic drugs (Phillips et al., 1986). The dose of
BCNU can be increased when it is given with autologous
bone marrow transplantation (ABMT) and such high doses
of BCNU can produce useful palliative effects in patients
whose grade gliomas recur after surgery and radiotherapy.
Two recent studies have reported a small number of long
term survivors with this approach (Fingert & Hochberg et
al., 1984; Phillips et al., 1986). The late onset of myelo-
suppression (usually after 10 days) when coupled with the
prompt recovery produced by autologous bone marrow
transplantation (usually before 20 days) would be expected
to result in a relatively short period of myelosuppression
even for high dose BCNU.
We have explored the use of high dose BCNU
(HDBCNU), 800-1,000 mg m-2 with autologous bone
marrow transplantation as the primary post-surgical
treatment of grade IV astrocytoma followed by full dose
radiotherapy. Our hypothesis was that the high dose of the
drug when given to tumours before irradiation might be
expected to result in improved penetration into the tumour
and an enhanced anti-tumour effect which could then be
supplemented by full dose radiotherapy. Tumour volume
reduction by drug treatment might also result in an
improved radiation effect. We expected that a short period
of myelosuppresssion would be associated with only
moderate treatment related toxicity and a short period of
hospitalisation.
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At the commencement of the study no data were available
for the pharmacokinetics of BCNU in high dose. We studied
these in order to determine the optimal scheduling for
autologous bone marrow transplantation.
Patients and methods
Patients
The 22 patients were aged less than 60 years with World
Health Organisation performance status (PS) less than 2
(WHO, 1979) and with histologically proven grade IV astro-
cytoma. They represented a consecutive series of patients
seen at the Royal Marsden Hospital between December 1983
and August 1986 who fulfilled the eligibility criteria and gave
informed consent. Surgical exploration and debulking was
the primary treatment and was performed at Atkinson
Morley's Hospital. There were 12 males, 10 females with
median age 47 years (range 32-58yrs). Nine patients were
aged less than 45yrs. Thirteen patients had PS 0 and 8
patients had PS 1. One patient was initially PS 1 but
deteriorated to PS 4 while waiting for marrow harvest.
Nineteen patients had experienced symptoms for less than 6
months before surgery. All patients were conscious before
craniotomy but 4 reported drowsiness. Fifteen tumours
showed the presence of pre-treatment necrosis histologically.
Eleven patients were blood group 0, 7 A, I B, I AB. Pre-
treatment blood counts were within the normal range in all
patients.
Minimum follow-up was one year from BCNU treatment
at the time of this analysis.
Methods
Pre-treatment evaluation included a history and physical
examination, full blood count, chest X-ray, biochemical
profile, and post-operative contrast-enhanced CT scan of the
brain. Pulmonary function tests were assessed in
symptomatic patients after HDBCNU or in those patients
undergoing a second treatment. Median time from surgery to
BCNU administration was 27 days (range 18-46).
Patients were nursed initially in a high dependency ward.
Bone marrow was harvested according to standard tech-
niques (Cornbleet et al., 1983) and stored at 4°C for 18
patients. In 4 cases it was cryopreserved in liquid nitrogen.
After full recovery from general anaesthesia they received
mannitol 10%, 200ml over 30 minutes and dexamethasone
8mg i.v. to reduce the risk of tumour swelling during the
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chemotherapy. Dexamethasone was continued at 4 mg 6
hourly for 48 hours and then returned to their post-operative
dosage. BCNU was dissolved in 6-9ml of absolute alcohol
and was injected over 10 minutes via a subclavian central
venous cannula. Fifteen patients received BCNU 800 mgm-2
and 7 patients 1gm-2; 3 patients treated at 800mgm-2
received 2 courses 4-6 weeks apart. The harvested bone
marrow was returned after 14h in 13 patients, 20h in 5
patients, and at 48 h (cryopreserved) in 4 patients. The
median number of nucleated cells infused was
1.96 x 108 kg- 1 (range 1.1-2.9).
On the day after the bone marrow infusion the patients
were returned to a general ward and discharged to out-
patient follow-up unless there were reasons unrelated to the
BCNU treatment which required inpatient care. Full blood
counts were checked twice during the first week after BCNU
and then on alternate days or daily depending on the trend
in cell counts. If total leucocyte count fell below 1 x 109 1 1
or platelets below 50 x109 1-1 they were readmitted for
observation until counts recovered to above these levels (17
patients) and for treatment of complications of the cytopenia
(3 patients).
Three patients received two doses of BCNU 800mgm2
separated by 6 weeks and both injections were given before
their radiotherapy. Separate marrow harvests were
performed before the second BCNU treatment.
After BCNU chemotherapy the patients proceeded to full
dose radiotherapy (55 Gy in 33 fractions in 612 weeks).
Median time from BCNU to radiotherapy was 27 days
(range 15-43 days). Patients whose disease progressed after
this initial combined modality treatment received carboplatin
or a drug combination (BOPP) consisting of BCNU,
vincristine, procarbazine and cisplatinum.
Time to progression was determined clinically and by CT
scan and measured from the date of surgery. Survival was
measured from the date of surgery.
Plasma concentrations of BCNU were determined by
isocratic high performance liquid chromatography and
pharmacokinetic parameters derived by standard procedures
(Workman et al., 1988).
Results
Toxicity
Mild nausea was common and lasted less than 24 hours
from the BCNU administration. All patients experienced
flushing, often associated with transient tachycardia and
hypotension, at the time of BCNU administration, which we
believe was related in part to the alcohol vehicle although a
direct effect of BCNU cannot be excluded (Henner et al.,
1986). Short lived acute myelosuppression occurred in all but
5 patients as shown in Tables I and II. Two patients
developed septicaemia and one bronchopneumonia during
the period of acute myelosuppression. These 3 patients were
treated successfully with antibiotics. There was no significant
relationship between either the dose of BCNU administered
or the time of ABMT and the severity or duration of acute
myelosuppression (Table II). The times to recovery of white
cells and platelets are shown in Figure 1. In 27% of patients
the white cell count did not fall below x 1091- and in
22% the platelets were never less than 50 x I0"1
(Figure 1).
An unexpected and irreversible late marrow failure (LMF)
occurred in 4 patients (median day of onset day 58, range
48-111). Three of these patients had their marrow returned
at 14hrs and 1 had marrow returned at 20hrs. No patient
with marrow returned at 48hrs had late marrow failure. Late
marrow failure directly contributed to death in 2 patients.
Three patients developed interstitial pneumonitis which
was fatal in 1, and contributed to death in another, while
one made a full recovery. Thirteen of 20 patients for whom
serial liver function tests are available had grade I WHO
toxicity (WHO, 1979); only 2 of these patients had clinically
significant liver syndromes, one of which was a fatal hepatic
failure, and the other a reversible severe hepatitis. There
were therefore a total of 4 treatment related deaths, 1 from
septicaemia associated with late marrow failure, 1 from
pneumonitis, 1 from pneumonitis with late marrow failure
and abnormal liver function, and 1 from a gastrointestinal
bleed due to liver failure with late marrow failure. Two other
early deaths occurred which were not apparently tumour-
related: herpes simplex encephalitis in 1 patient and
pulmonary embolus in another.
Anti-tumour effect
There was clinical improvement on the overall treatment
regimen and all patients except the patient with fatal herpes
simplex encephalitis left hospital. However, tumour volume
changes on CT scan were difficult to interpret and we feel
that partial or complete remission rates in terms of volume
regression due to BCNU or to BCNU plus radiotherapy
cannot be defined in this disease by these methods. All of
the patients who survived to have follow-up scans showed
some improvements but in no case did scans become normal.
Progression was defined as unequivocal tumour growth on
the CT scan or clinical deterioration with a CT scan
compatible with progression. Time to progression is shown
in Figure 2. The median time to disease progression is 14
months.
Five of the 22 patients remain alive at the time of writing.
One of these patients has evidence of disease progression at
27 months from surgery; 4 patients have no evidence of
disease progression at 11, 12, 18 and 42 months from
surgery (Figure 3). The median survival time is 17 months
with actuarial probability of survival at 2 yrs of 25%.
Among the 3 patients who received two treatments with
BCNU before radiotherapy one died with late marrow
failure at 5 months, one died of disease progression at 39
months and one is alive without disease at 42 months.
Pharmacokinetics
Detailed pharmacokinetic studies were performed in 5
patients treated at 800mgm-2 and are reported in detail
elsewhere (Workman et al., 1988). Peak plasma concen-
trations ranged from 11.9-23.5ygml-' (mean 12.8jpgml-1).
The mean a and P phase half-lives were 32min and 4.26h
respectively and the clearance was 1121 h-1 m-2. Low
Table I Severity and duration of acute myelosuppression
Median (range) Median (range) Median (range)
Nadir Day onset Day recovery Median (range)
( x109 1-) (<1 x 1091-1) (>I x 1091-1) Duration
WCC 0.6 12.5 19 4 days
(0.1-5.6) (7-20) (13-26) (0.17)
(<50 x 1091-1) (>50 x 1091-1)
Plt 20 14 22 7 days
(11-79) (9-20) (16-33) (0-20)THERAPY OF GRADE IV ASTROCYTOMA 781
Table II Acute myelosuppression analysed by BCNU dosage, time
of BM return and number of BM nucleated cells
Median day for
Median day for recovery of
recovery of wbc platelets
>Ix1091-1 >50x109l1-
Dose 800mgm-2 22.5 226
Time 14h 20 23
ABMT 20h 19 19.5
48h 20.5 30
Nucleated <2x1091-1 20 27
BMcells >2x1091-1 17 21
No differences are significant using a Wilcoxon Rank Sum Test.
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Figure 3 Cumulative probability of survival (time after surgery).
Table III Percent survival
6m 12m 18m 2yrs
Estimated for comparable group
from MRC studies 82 48 21 19
Observed after high dose BCNU 68 59 53 25
Note: The figure represents a comparison of the observed results
in this study to the results predicted for a comparable group of
patients from the prognostic index established in the MRC studies.
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A a tethe prognosis of patients with high grade glioma when included Actu tto -event p of therecover of t in their studies. The important prognostic variables are age,
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of surgery and a history of epileptic fits. A prognostic index
based upon these variables has been produced and has been
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dose and fractionation studies (MRC, 1983; MRC, 1988;
Freedman, L., personal communication). We have used this
index to construct survival figures for a group of patients
comparable to those treated in this study. This calculated
survival for comparable patients treated in the MRC study is
shown in Table III and compared to the observed survival in
our study.
Years since surgery
Figure 2 Cumulative probability plot for time to progression
(time after high dose BCNU).
concentrations of BCNU remained detectable at 24h. This
may have adversely affected the bone marrow autografts
returned at <20h and probably caused the unexpected late
myelosuppression seen in 4 of our patients.
Comparison of results to radiation alone after surgery
We have compared the results in these patients with those
treated in recent Medical Research Council trials of patients
with malignant high grade glioma (MRC, 1983; Freedman,
L., personal communication). The Brain Tumour Working
Discussion
Although a relatively small number of patients have been
treated in this programme the follow-up is now long and we
feel some conclusions can be drawn cautiously from the
data.
The acute subjective toxicity of BCNU at these doses was
mild and the period of myelosuppression was short. This
resulted in a minimal amount of hospitalisation with much
less supportive care than for alternative high dose chemo-
therapy regimens. In this study, the treatment was compli-
cated by an unexpected late fall in peripheral blood
leucocytes and platelets in 4 patients. It seems likely that the
low concentrations of BCNU present at the time of marrow
return in the first 18 patients resulted in toxicity to early
bone marrow stem cells and late marrow failure. This
complication was not seen in cryopreserved bone marrow
returned at 48 hours after BCNU in 4 patients in this study
and in subsequent studies with high dose BCNU in other
tumours late return of the bone marrow has avoided these
complications. Unfortunately, non-haemopoietic toxicity was
a substantial problem. Lung and liver toxicity contributed to
3 deaths in our series. We saw no evidence of encephalo-
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myelopathy but this has been described after high dose
BCNU by others and should be included among the list of
possible major complications (Burger et al., 1981; Wolff et
al., 1987). The overall incidence of fatal non-haemopoietic
toxicity in our series (3/22 patients) was lower than that
reported by Wolff et al. (1987). Among their 19 patients,
they had 4 cases of fatal pneumonitis, with 2 cases of serious
encephalomyelopathy as well as 4 cases of non-fatal
pneumonitis. This higher incidence of serious non-
haemopoietic toxicity is likely to be related to the higher
dose of BCNU (1,050 mgm2) which they used and perhaps
the encephalopathy might have resulted from their use of the
drug after radiation.
Our own observations together with those of Wolff &
colleagues (1987) suggest that there is little room for further
dose escalation of BCNU without running the risk of a high
incidence of potentially fatal non-haemopoietic toxicity.
We had the impression that these results compared
favourably with our historical experience of survival of
patients with grade IV astrocytoma treated by radiotherapy
alone (Bloom, 1978, 1982). Examination of survival curves
suggested that the addition of high dose BCNU might result
in a delay in progression of the tumour. Unfortunately, the
number of long term survivors is still very small and
disappointing. The validity of this impression could only be
tested with any certainty in a large prospective randomised
trial. However, such a trial would be a major undertaking
involving extensive use of resources in many institutions. We
therefore, sought to examine the results further by con-
structing an artificial historical control group from the MRC
series balancing that group for the known prognostic
variables. We are aware of the pitfalls of such an analysis.
Our patients were treated in a single institution with a single
standard of supportive care that may differ from those in the
many institutions contributing to the MRC studies. Even the
use of multivariate analysis to establish the important prog-
nostic variables in the MRC series does not allow us to
balance our groups for the many unidentified factors which
influence the outcome of treatment in these circumstances.
Nevertheless, we feel the results of this comparison are
interesting and worth describing.
There appears to be an excess of early deaths in our
patients as a result of treatment toxicity when compared to
the MRC series. However, this is followed by a much slower
death rate through the remaining two years of comparison
so that significantly more patients who were treated with
high dose BCNU are alive at 18 months than would be
predicted by the MRC data. Unfortunately, this improved
survival is not sustained and there is little difference in the
survival rate beyond 2 years. These figures support the view
that there is a delay in death resulting from the use of high
dose BCNU but that it does not establish an increased cured
sub-population of patients.
Although we have successfully established a relatively non-
toxic way of delivering high dose chemotherapy with the
present drug of choice in the treatment of high grade glioma,
the benefits appear to be small. We do not believe that a
randomised prospective trial is now justified for grade IV
astrocytoma. Further studies with increased doses of BCNU
would probably be hazardous and we do not propose to
continue with this approach. The results may have some
relevance to the choice of new chloroethyl nitrosoureas and
related agents for evaluation in brain tumours. Compounds
that sustain their efficacy against glioma cells and penetrate
the brain well would be of interest if they had reduced lung
and liver toxicity, even if they remained myelosuppressive.
The myelosuppression can be readily and quite simply
avoided by autologous bone marrow transplantation and
this could result in a safer and more effective use of this
approach in the future.
We are most grateful to the Clinical Trials Office of the MRC for
access to their unpublished data and to the staff of the Royal
Marsden Hospital for their excellent patient care. These studies are
supported by the Cancer Research Campaign and the Medical
Research Council.
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